Skip to main content
Premium Trial:

Request an Annual Quote

Trustee Pledges $1M to Sanford-Burnham toward Commercialization Efforts

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sanford-Burnham Medical Research Institute has received a $1 million pledge from longtime trustee Arthur Brody toward commercializing the institution's discoveries into drug treatments.

The gift from Brody — a philanthropist and the president of Brosoar, a management and administrative service for business and personal investments in Rancho Santa Fe, Calif., — will create the Art Brody Innovation Fund, "which will advance promising research that might otherwise be stalled due to lack of financial support," the institute said in a statement.

According to Sanford-Burnham, the fund will be used for refining the development of early drug candidates at the Conrad Prebys Center for Chemical Genomics, advancing many of those medicines into clinical trials, and attracting investors.

The fund will also provide seed capital for companies formed to commercialize Sanford-Burnham discoveries, the institute said in a statement.

Brody is also a co-founder and member of the advisory council of Sorrento Ventures, a San Diego-based venture capital firm.

In 2008, he helped launch a venture philanthropy fund for Sanford-Burnham predecessor Burnham Institute for Medical Research, to be used for later-stage research projects and for potential investments in Burnham spinout companies.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.